HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): George E. Sarris Philip E. Oyer Edward B. Stinson Bruce A. Reitz Norman E. Shumway Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sarris, G. E. Articles by Shumway, N. E. Search for Related Content PubMed PubMed Citation Articles by Sarris, G. E. Articles by Shumway, N. E.

J Thorac Cardiovasc Surg 1994;108:240-252
© 1994 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

Cardiac transplantation: The Stanford experience in the cyclosporine era

Stanford, Calif.

From the Division of Cardiovascular Medicine, ^bDepartment of Pathology, ^c and Department of Cardiothoracic Surgery, ^a Stanford University School of Medicine, Stanford, Calif.

Address for reprints: Norman E. Shumway, MD, PhD, Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305.

Abstract

We analyzed our experience with 496 patients who underwent primary cardiac transplantation since the introduction of cyclosporine immunosuppression (Dec. 16, 1980, to Jan. 7, 1993). There were 388 male and 108 female patients. Mean recipient age was 40 ± 16 years (range 0.1 to 70 years, median 44 years). Recipient diagnoses included coronary disease in 188, idiopathic cardiomyopathy in 196, viral cardiomyopathy in 35, and congenital heart disease in 28 patients. Donor age was 25 ± 10 years (range 1 to 53 years, median 24 years). Graft ischemic time was 148 ± 57 minutes (range 38 to 495 minutes, median 149 minutes). Operative mortality (hospital death) rate was 7.9% ± 1.3% (70% confidence intervals). Multivariate logistic regression analysis revealed that (higher) pulmonary vascular resistance and gender (female) were the only independent predictors of hospital death (p < 0.05). Actuarial survival estimates for all patients at 1, 5, and 10 years are 82% ± 1.7% (83% ± 1.8% adult, 77% ± 5.2% pediatric), 61% ± 2.5% (65% ± 2.5% adult, 64% ± 6.6% pediatric), and 41% ± 3.7% (40% ± 4% adult, 54% ± 8.6% pediatric), respectively. For 232 patients treated with triple-drug immunosuppression and induction with OKT3 since 1987, survival estimates at 1 and 5 years are 82% ± 2.6% and 67% ± 3.7%, respectively. Causes of death for the entire group were rejection in 29 (14% of deaths), infection in 69 (34%), graft coronary disease in 36 (18%), nonspecific graft failure in 6 (3%), malignancy in 19 (10%), stroke in 6 (3%), pulmonary hypertension in 6 (3%), and other causes in 30 (15%) patients. Actuarial freedom from rejection at 3 months, 1 year, and 5 years was 21% ± 1.9%, 14% ± 1.7%, and 7.2% ± 1.5%, respectively (±1 standard error of the mean). Estimates of freedom from rejection-related death at 1, 5, and 10 years were 96% ± 1%, 93% ± 1.4%, and 93% ± 1.4%, respectively. Actuarial freedom from any infection at 3 months and at 1 and 5 years was 40% ± 2.3%, 27% ± 2.1%, and 15% ± 2.0% and from infection-related death, 95% ± 1.0%, 93% ± 1.2%, and 85% ± 1.9%, respectively. Actuarial freedom from (angiographic or autopsy proved) graft coronary artery disease at 1, 5, and 10 years was 95% ± 1.2%, 73% ± 2.7%, and 65% ± 3.6% and from coronary disease–related death or retransplantation 98% ± 0.7%, 84% ± 2.2%, and 66% ± 4.3%, respectively. Multivariate (Cox model) proportional hazard regression analysis revealed that (older) recipient age and race (nonwhite) were independent predictors of late (as opposed to hospital) death (p < 0.05). Immunosuppressive protocol was an independent predictor (p < 0.05) of freedom from rejection (but not from late death or from rejection-related death). These data demonstrate satisfactory long-term results of cardiac transplantation for treatment of patients with end-stage heart disease. (J THORAC CARDIOVASC SURG 1994;108:240-52)

This article has been cited by other articles:

				L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578. [Full Text]

				A. Y. Sheikh, M. P. Pelletier, and R. C. Robbins Heart-Lung and Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1579 - 1608. [Full Text]

				C. G. Densem, I. V. Hutchinson, N. Yonan, and N. H. Brooks Influence of IFN-{gamma} polymorphism on the development of coronary vasculopathy after cardiac transplantation Ann. Thorac. Surg., March 1, 2004; 77(3): 875 - 880. [Abstract] [Full Text] [PDF]

				T. Hattori, H. Shimokawa, M. Higashi, J. Hiroki, Y. Mukai, K. Kaibuchi, and A. Takeshita Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice Circ. Res., January 9, 2004; 94(1): 46 - 52. [Abstract] [Full Text] [PDF]

				B. T. Bethea, D. D. Yuh, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1427 - 1460. [Full Text]

				L. B. Balsam, D. D. Yuh, R. C. Robbins, and B. A. Reitz Heart-Lung and Lung Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1461 - 1490. [Full Text]

				J.-P. Remadi, O. Baron, J. C. Roussel, O. Al Habash, M. Treilhaud, P. Despins, D. Duveau, and J.-L. Michaud Myocardial preservation using celsior solution in cardiac transplantation: early results and 5-year follow-up of a multicenter prospective study of 70 cardiac transplantations Ann. Thorac. Surg., May 1, 2002; 73(5): 1495 - 1499. [Abstract] [Full Text] [PDF]

				R. John, H. A. Rajasinghe, J. M. Chen, A. D. Weinberg, P. Sinha, D. M. Mancini, Y. Naka, M. C. Oz, C. R. Smith, E. A. Rose, et al. Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy Ann. Thorac. Surg., August 1, 2001; 72(2): 440 - 449. [Abstract] [Full Text] [PDF]

				R. John, H. A. Rajasinghe, S. Itescu, S. Suratwalla, K. Lietz, A. D. Weinberg, A. Kocher, D. M. Mancini, R. E. Drusin, M. C. Oz, et al. Factors affecting long-term survival (>10 years) after cardiac transplantation in the cyclosporine era J. Am. Coll. Cardiol., January 1, 2001; 37(1): 189 - 194. [Abstract] [Full Text] [PDF]

				N. F. Mulla, J. K. Johnston, L. Vander Dussen, W. L. Beeson, R. E. Chinnock, L. L. Bailey, and R. L. Larsen Late rejection is a predictor of transplant coronary artery disease in children J. Am. Coll. Cardiol., January 1, 2001; 37(1): 243 - 250. [Abstract] [Full Text] [PDF]

				T. D. Crabtree, S. J. Pelletier, T. G. Gleason, T. L. Pruett, and R. G. Sawyer Gender-Dependent Differences in Outcome After the Treatment of Infection in Hospitalized Patients JAMA, December 8, 1999; 282(22): 2143 - 2148. [Abstract] [Full Text] [PDF]

				S. K. Epstein and V. Vuong Lack of Influence of Gender on Outcomes of Mechanically Ventilated Medical ICU Patients Chest, September 1, 1999; 116(3): 732 - 739. [Abstract] [Full Text] [PDF]

				R.-B. Hsu, S.-H. Chu, S.-S. Wang, W.-J. Ko, N.-K. Chou, C.-M. Lee, M.-F. Chen, and Y.-T. Lee Low incidence of transplant coronary artery disease in chinese heart recipients J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1573 - 1577. [Abstract] [Full Text] [PDF]

				R. C. Robbins, C. W. Barlow, P. E. Oyer, S. A. Hunt, J. L. Miller, B. A. Reitz, E. B. Stinson, and N. E. Shumway THIRTY YEARS OF CARDIAC TRANSPLANTATION AT STANFORD UNIVERSITY J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 939 - 951. [Abstract] [Full Text] [PDF]

				B. L. Knisely, L. A. Mastey, J. Collins, J. E. Kuhlman, and A. N. Leung Imaging of Cardiac Transplantation Complications RadioGraphics, March 1, 1999; 19(2): 321 - 341. [Abstract] [Full Text] [PDF]

				D. H. Walter, J. Haendeler, J. Galle, A. M. Zeiher, and S. Dimmeler Cyclosporin A Inhibits Apoptosis of Human Endothelial Cells by Preventing Release of Cytochrome C From Mitochondria Circulation, September 22, 1998; 98(12): 1153 - 1157. [Abstract] [Full Text] [PDF]

				R. Hetzer, W. Albert, M. Hummel, M. Pasic, M. Loebe, H. Warnecke, A. Haverich, and H. G. Borst Status of Patients Presently Living 9 to 13 Years After Orthotopic Heart Transplantation Ann. Thorac. Surg., December 1, 1997; 64(6): 1661 - 1668. [Abstract] [Full Text]

				C. Shi, W.-S. Lee, M. E. Russell, D. Zhang, D. L. Fletcher Jr, J. B. Newell, and E. Haber Hypercholesterolemia Exacerbates Transplant Arteriosclerosis via Increased Neointimal Smooth Muscle Cell Accumulation : Studies in Apolipoprotein E Knockout Mice Circulation, October 21, 1997; 96(8): 2722 - 2728. [Abstract] [Full Text]

				H. Lou, T. Kodama, Y. J. Zhao, P. Maurice, Y. N. Wang, N. Katz, and M. L. Foegh Inhibition of Transplant Coronary Arteriosclerosis in Rabbits by Chronic Estradiol Treatment Is Associated With Abolition of MHC Class II Antigen Expression Circulation, December 15, 1996; 94(12): 3355 - 3361. [Abstract] [Full Text]

				M. Pasic, M. Loebe, M. Hummel, O. Grauhan, J. Hofmeister, Y. Weng, and R. Hetzer Heart Transplantation: A Single-Center Experience Ann. Thorac. Surg., December 1, 1996; 62(6): 1685 - 1690. [Abstract] [Full Text]

				E. A. Bocchi, G. Bellotti, A. O. Mocelin, D. Uip, F. Bacal, M. L. Higuchi, V. Amato-Neto, A. Fiorelli, N. A. G. Stolf, A. D. Jatene, et al. Heart Transplantation for Chronic Chagas' Heart Disease Ann. Thorac. Surg., June 1, 1996; 61(6): 1727 - 1733. [Abstract] [Full Text]

				H. A. Valantine and J. S. Schroeder Recent Advances in Cardiac Transplantation N. Engl. J. Med., September 7, 1995; 333(10): 660 - 662. [Full Text]